These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 15602106)
1. Levodopa infusion therapy in Parkinson disease: state of the art in 2004. Nyholm D; Aquilonius SM Clin Neuropharmacol; 2004; 27(5):245-56. PubMed ID: 15602106 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. Nyholm D Clin Pharmacokinet; 2006; 45(2):109-36. PubMed ID: 16485914 [TBL] [Abstract][Full Text] [Related]
3. Duodenal levodopa infusion for the treatment of Parkinson's disease. Samanta J; Hauser RA Expert Opin Pharmacother; 2007 Apr; 8(5):657-64. PubMed ID: 17376020 [TBL] [Abstract][Full Text] [Related]
6. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Nutt JG; Carter JH; Lea ES; Woodward WR Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications. Müller T Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910 [TBL] [Abstract][Full Text] [Related]
8. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life. Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551 [TBL] [Abstract][Full Text] [Related]
9. [Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease]. Antonini A; Jost WH Fortschr Neurol Psychiatr; 2018 Sep; 86(S 01):S5-S9. PubMed ID: 30107620 [TBL] [Abstract][Full Text] [Related]
10. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release. Rascol O Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197 [TBL] [Abstract][Full Text] [Related]
11. Necessity of long-term alertness in levodopa-carbidopa intestinal gel infusion for PD patients. Klostermann F; Bojarski C; Marzinzik F; Maier A; Schindlbeck KA; Ehlen F Mov Disord; 2017 Feb; 32(2):300-301. PubMed ID: 27859611 [No Abstract] [Full Text] [Related]
12. Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa. Melamed E; Zoldan J; Galili-Mosberg R; Ziv I; Djaldetti R J Neural Transm Suppl; 1999; 56():173-83. PubMed ID: 10370911 [TBL] [Abstract][Full Text] [Related]
13. Novel levodopa formulations in the treatment of Parkinson's disease. Pilleri M; Antonini A Expert Rev Neurother; 2014 Feb; 14(2):143-9. PubMed ID: 24428803 [TBL] [Abstract][Full Text] [Related]
14. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety. Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940 [TBL] [Abstract][Full Text] [Related]
15. Irregular gastrointestinal drug absorption in Parkinson's disease. Nyholm D; Lennernäs H Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):193-203. PubMed ID: 18248312 [TBL] [Abstract][Full Text] [Related]